

## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lncn20>

### SYNTHESIS AND ANTIVIRAL EVALUATION OF C-4-HYDRAZIDE DERIVATIVES OF 2',3'-DIDEOXYCYTIDINE

Valérie Boudou-Vivet<sup>a</sup>, Christophe Mathé<sup>a</sup> & Gilles Gosselin<sup>b</sup>

<sup>a</sup> Université Montpellier II, Laboratoire de Chimie Organique Biomoléculaire de Synthèse, UMR 5625 CNRS-UM II, Place E. Bataillon, Montpellier, Cedex 5, 34095, France

<sup>b</sup> Université Montpellier II, Laboratoire de Chimie Organique Biomoléculaire de Synthèse, UMR 5625 CNRS-UM II, Place E. Bataillon, Montpellier, Cedex 5, 34095, France  
Published online: 07 Feb 2007.

To cite this article: Valérie Boudou-Vivet, Christophe Mathé & Gilles Gosselin (2001) SYNTHESIS AND ANTIVIRAL EVALUATION OF C-4-HYDRAZIDE DERIVATIVES OF 2',3'-DIDEOXYCYTIDINE, *Nucleosides, Nucleotides and Nucleic Acids*, 20:4-7, 1029-1032, DOI: [10.1081/NCN-100002484](https://doi.org/10.1081/NCN-100002484)

To link to this article: <http://dx.doi.org/10.1081/NCN-100002484>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, 20(4–7), 1029–1032 (2001)

## SYNTHESIS AND ANTIVIRAL EVALUATION OF C-4-HYDRAZIDE DERIVATIVES OF 2',3'-DIDEOXYCYTIDINE

Valérie Boudou-Vivet, Christophe Mathé,  
and Gilles Gosselin\*

Laboratoire de Chimie Organique Biomoléculaire de Synthèse,  
UMR 5625 CNRS-UM II, Université Montpellier II, Place E. Bataillon,  
34095 Montpellier Cedex 5, France

### ABSTRACT

Syntheses of three hitherto unknown derivatives of 2',3'-dideoxycytidine, namely C-4-(salicylic hydrazide)-ddC, C-4-(*N*-butyloxycarbonyl-isoleucine hydrazide)-ddC and its *N*-unprotected chlorhydrate salt have been carried out. These compounds do not induce inhibition of HIV-1 replication in cell culture experiments. Nevertheless, the modifications on the base moiety increased in all cases the lipophilicity of the parent molecule with an acceptable water solubility compared to ddC.

### INTRODUCTION

During the last decade, significant progress has been accomplished in the discovery of new antiviral agents and in the therapeutic approaches against human immunodeficiency virus (HIV) infection (1). To date, six nucleoside analogues have been approved by the Food and Drug Administration for the treatment of AIDS. However, these compounds suffer from several drawbacks such as low oral bioavailability, chemical or enzymatic instability or non appropriate biodistribution (2,3).

Within the framework of our research program on the improvement of pharmacological and pharmacokinetic properties of nucleoside analogues with antiviral

---

\*Corresponding author.


properties, we have designed hitherto unknown derivatives of 2',3'-dideoxycytidine (ddC). Here, we report the preparation and the studies of *C*-4-(salicylic hydrazide)-ddC, (**4**) *C*-4-(*N*-butyloxycarbonyl-isoleucine hydrazide)-ddC (**6**) and its *N*-unprotected chlorhydrate salt (**7**).

### SYNTHESES

From a synthetic viewpoint, the target compounds (**4**, **6** and **7**) were prepared from commercially available 2',3'-dideoxyuridine (ddU).

Firstly, the 5'-hydroxyl function of ddU was suitably protected with a benzoyl group to afford compound (**1**). Then, the *C*-4 position of the base was activated *via* triisopropylbenzene-sulfonyl chloride treatment to give (**2**), as a key intermediate.

Reaction of **2** with commercially available salicylic hydrazide provided compound (**3**), which upon treatment with methanolic ammonia gave the first desired molecule (**4**) in 70% yield. Isoleucine hydrazide, (**5**) prepared by action of hydrazine on *N*-Boc-isoleucine in the presence of BOP and triethylamine in dichloromethane) was reacted with intermediate (**2**) to give a fully protected derivative which upon treatment with methanolic ammonia afforded *C*-4-(*N*-butyloxycarbonyl-isoleucine hydrazide)-ddC (**6**). Finally, removal of the Boc protecting group from **6** afforded the last desired compound (**7**).



Scheme.



Table.

	Partition Coefficient		Solubility g/l
	P	Log P	
ddC	0.04	-1.36	63
<b>4</b>	1.19	0.07	15
<b>6</b>	8.19	0.91	4
<b>7</b>	0.077	-1.06	55

Structural assignments for compounds **4**, **6** and **7** were based on elemental analysis and physicochemical properties.

### LIPOPHILICITY AND SOLUBILITY STUDIES

The lipophilicity of the new compounds (**4**, **6** and **7**) was determined measuring their partition coefficient between octanol and water. All of them show a higher lipophilicity than the reference molecule ddC, with an acceptable water solubility.

### ANTIVIRAL EVALUATION

Compounds **4**, **6** and **7** were tested for their *in vitro* inhibitory effects on the replication of HIV-1 in CEM-SS and MT-4 cell systems. None of these compounds showed significant antiviral activity nor cytotoxicity at the highest concentration tested (100  $\mu$ M). In the same assays, ddC had EC<sub>50</sub> of 0.023  $\mu$ M in CEM-SS and  $\geq 1$   $\mu$ M in MT-4 cells.

### CONCLUSION

From the present work, it appears that the C-4 hydrazide derivatives of ddC do not induce inhibition of HIV-1 replication in cell culture experiments. Among the several hypotheses than can explain this lack of activity, the inability of these compounds to release appropriately (intra or extra-cellularly) the parent ddC nucleoside, as well as their chemical or enzymatic instability (with cleavage of the glycosidic bond), can be proposed. Nevertheless, the modifications on the base moiety increased in all cases the lipophilicity of the parent molecule with an acceptable water solubility compared to ddC. Synthesis and antiviral evaluation of other ddC derivatives bearing various groups on the base moiety with different linkers are currently in progress in our laboratory.

### ACKNOWLEDGMENTS

These investigations were supported by grants from the "Agence Nationale de la Recherche sur le SIDA" (ANRS) France. We gratefully acknowledge the support of the New York State Office of Mental Health, Inc., 270 Madison Avenue, New York, New York 10016



Dr A. M. Aubertin (Université Louis Pasteur, Strasbourg, France) for the biological evaluations. One of us (V. B.-V.) is particularly grateful to the ANRS, France for a postdoctoral fellowship.

### REFERENCES

1. Vandamme, A.-M.; Van Vaerenbergh, K.; De Clercq, E. *Antiviral Chem. & Chemother.*, **1998**, 9, 187–203.
2. Geleziunas, R.; Schipper, H.M.; Wainberg, M.A. *AIDS*, **1992**, 6, 1411–1426.
3. Atwood, W.J.; Berger, J.R.; Kaderman, R.; Tornatore, C.S.; Major, E.O. *Clin. Microbiol. Rev.* **1993**, 6, 339–366.



## **Request Permission or Order Reprints Instantly!**

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

**[Order now!](#)**

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002484>